AstraZeneca to acquire Alexion in $39 billion deal. Alexion Highlights Commercial, Clinical and Financial Progress at the 39th Annual J.P. Morgan Healthcare Conference Jan 12 2021; Alexion to Present at the 39th Annual J.P. Morgan Healthcare Conference Jan 05 2021; AstraZeneca to Acquire Alexion, Accelerating the Company's Strategic and Financial Development Dec 12 2020; Alexion Receives Marketing Authorization from European … Pascal Soriot has led the charge to make AstraZeneca one of the first pharmaceutical companies in the world to produce a vaccine against Covid-19. In a statement announcing the deal, AstraZeneca said it will use its existing presence in emerging markets to accelerate the sales of Alexion’s drugs. Drugmaker AstraZeneca has agreed to buy US biotechnology group Alexion in a $39bn deal, marking the biggest agreement struck by a pharmaceutical company since … AstraZeneca on Saturday said it would acquire Alexion Pharmaceuticals for $39 billion. Alexion is a global biopharmaceutical company focused on developing life-changing therapies for people living with rare disorders. Alexion Highlights Commercial, Clinical and Financial Progress at the 39th Annual J.P. Morgan Healthcare Conference Jan 12 2021; Alexion to Present at the 39th Annual J.P. Morgan Healthcare Conference Jan 05 2021; AstraZeneca to Acquire Alexion, Accelerating the Company's Strategic and Financial Development Dec 12 2020 AstraZeneca (AZN) has refiled its planned takeover of Alexion (ALXN) with U.S AstraZeneca/Alexion: the odd couple Long-term results could be rewarding: investors should give this the benefit of the doubt Search FT.com for Alexion Pharmaceuticals Inc Show more articles It expects the deal will enable around U$500m in pre-tax savings, including from job cuts in administrative functions, the FT reports. AstraZeneca PLC is resetting the clock to give the Federal Trade Commission more time to review its roughly $39 billion bid for Alexion Pharmaceuticals Inc., the … Under the deal, Alexion shareholders will receive roughly $175 per share, $60 of which would be cash and the rest in shares. AstraZeneca approached Alexion in the summer, leading to a four-month “back and forth”, which mainly focused on the headline price, according to a person familiar with the matter. AstraZeneca is in the midst of a $39-billion acquisition of US biotech firm Alexion /GETTY IMAGES NORTH AMERICA/AFP/File .